Lamdong Pharmaceutical Joint Stock Company - Laporan Laba Rugi (TTM)

Lamdong Pharmaceutical Joint Stock Company
VN ˙ HNX
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Lamdong Pharmaceutical Joint Stock Company menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 273,079 161,902 171,086 169,250 182,648 187,415 180,649 182,592 187,841 186,001 188,473 190,793 191,496 217,958 233,539 235,837
Change (%) -40.71 5.67 -1.07 7.92 2.61 -3.61 1.08 2.88 -0.98 1.33 1.23 0.37 13.82 7.15 0.98
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 227,158 140,678 145,610 141,357 147,855 149,895 147,218 148,802 149,386 148,835 147,197 143,230 141,410 153,567 160,485 161,383
Change (%) -38.07 3.51 -2.92 4.60 1.38 -1.79 1.08 0.39 -0.37 -1.10 -2.69 -1.27 8.60 4.50 0.56
% of Revenue 83.18 86.89 85.11 83.52 80.95 79.98 81.49 81.49 79.53 80.02 78.10 75.07 73.84 70.46 68.72 68.43
Gross Operating Profit 45,921 21,225 25,476 27,893 34,793 37,519 33,432 33,790 38,455 37,166 41,276 47,563 50,087 64,390 73,054 74,454
Change (%) -53.78 20.03 9.48 24.74 7.84 -10.90 1.07 13.81 -3.35 11.06 15.23 5.31 28.56 13.45 1.92
% of Revenue 16.82 13.11 14.89 16.48 19.05 20.02 18.51 18.51 20.47 19.98 21.90 24.93 26.16 29.54 31.28 31.57
SG&A 65,603 41,013 39,876 49,598 58,699 62,833 63,730 54,103 51,973 49,512 48,128 49,008 48,060 51,110 58,653 62,263
Change (%) -37.48 -2.77 24.38 18.35 7.04 1.43 -15.11 -3.94 -4.73 -2.80 1.83 -1.94 6.35 14.76 6.15
% of Revenue 24.02 25.33 23.31 29.30 32.14 33.53 35.28 29.63 27.67 26.62 25.54 25.69 25.10 23.45 25.11 26.40
R&D
Change (%)
% of Revenue
OpEx 292,761 181,691 185,486 190,955 206,555 212,729 210,947 202,905 201,359 198,347 195,325 192,238 189,469 204,678 219,138 223,646
Change (%) -37.94 2.09 2.95 8.17 2.99 -0.84 -3.81 -0.76 -1.50 -1.52 -1.58 -1.44 8.03 7.07 2.06
% of Revenue 107.21 112.22 108.42 112.82 113.09 113.51 116.77 111.12 107.20 106.64 103.64 100.76 98.94 93.91 93.83 94.83
Operating Income -19,682 -19,788 -14,400 -21,705 -23,906 -25,314 -30,298 -20,313 -13,518 -12,347 -6,852 -1,445 2,027 13,280 14,401 12,191
Change (%) 0.54 -27.23 50.73 10.14 5.89 19.69 -32.96 -33.45 -8.66 -44.51 -78.91 -240.29 555.08 8.44 -15.34
% of Revenue -7.21 -12.22 -8.42 -12.82 -13.09 -13.51 -16.77 -11.12 -7.20 -6.64 -3.64 -0.76 1.06 6.09 6.17 5.17
Interest Expense -7,165 -2,210 -1,993 -1,808 -4,618 -7,544 -8,952 -7,037 -7,092 -7,027 -6,693 -6,969 -7,300 -4,979 -5,173 -3,797
Change (%) -69.15 -9.81 -9.31 155.44 63.37 18.66 -21.40 0.79 -0.93 -4.74 4.12 4.75 -31.80 3.91 -26.60
% of Revenue -2.62 -1.37 -1.17 -1.07 -2.53 -4.03 -4.96 -3.85 -3.78 -3.78 -3.55 -3.65 -3.81 -2.28 -2.22 -1.61
Net Income -5,153 37,870 44,478 29,921 25,319 -38,891 -46,886 -29,197 -20,238 -20,105 -13,554 -9,036 -6,075 6,919 7,756 7,332
Change (%) -834.89 17.45 -32.73 -15.38 -253.60 20.56 -37.73 -30.68 -0.66 -32.59 -33.33 -32.77 -213.89 12.09 -5.46
% of Revenue -1.89 23.39 26.00 17.68 13.86 -20.75 -25.95 -15.99 -10.77 -10.81 -7.19 -4.74 -3.17 3.17 3.32 3.11

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista